USPTO Art Unit 1656 Prosecution Statistics

Art Unit Information

Art Unit: 1656
Group: 1650
Tech Center: 1600
Total Cases: 13,705
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19328055PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESSeptember 2025December 2025Allow300YesNo
19310812REVERSE TRANSCRIPTASE VARIANTSAugust 2025November 2025Allow300YesNo
19212289STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLESMay 2025August 2025Allow301YesNo
19173657EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEApril 2025August 2025Allow510YesNo
19173652EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDEApril 2025December 2025Allow820YesNo
19095861COMPOSITIONS, KITS, AND METHODS FOR IN VITRO TRANSCRIPTIONMarch 2025October 2025Allow701YesNo
19074055POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDESMarch 2025September 2025Allow610NoNo
19071345PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFMarch 2025October 2025Allow810YesNo
19048328NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINFebruary 2025December 2025Abandon1010NoNo
19048080NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXINFebruary 2025January 2026Abandon1120NoNo
19026516ERGOTHIONEINE-PRODUCING ENGINEERED BACTERIA AND CONSTRUCTION METHOD AND USE THEREOFJanuary 2025October 2025Allow911YesNo
18879948NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAMEDecember 2024June 2025Allow600YesNo
18879995NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAMEDecember 2024May 2025Allow500NoNo
18879104MODIFIED MICROORGANISM OF GENUS CORYNEBACTERIUM PRODUCING L-GLUTAMIC ACID AND METHOD FOR PRODUCING L-GLUTAMIC ACID USING SAMEDecember 2024August 2025Allow801YesNo
18984347RECOMBINANT HUMANIZED TYPE III COLLAGEN MICROSPHERE WITH INNOVATIVE SPATIAL STRUCTURE, AND DESIGN, PREPARATION PROCESS AND USETHEREOFDecember 2024July 2025Allow711YesNo
18984162CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATIONDecember 2024May 2025Allow500YesNo
18977534STRAINS AND METHODS FOR THE CONTINUOUS PRODUCTION OF PRODUCTS BY GAS FERMENTATIONDecember 2024March 2026Abandon1511NoNo
18970552S. PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAMEDecember 2024May 2025Allow510NoNo
18965675NOVEL CRISPR ENZYMES AND SYSTEMSDecember 2024January 2026Allow1421YesNo
18870088METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA)November 2024February 2025Allow300YesNo
18948388COMPOSITION COMPRISING COLLAGENASE, CALCIUM, HISTIDINE, AND GLYCINE, AND METHOD FOR STABILIZING COLLAGENASENovember 2024October 2025Allow1120NoNo
18926774PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOFOctober 2024May 2025Allow621NoNo
18919946FUSION POLYPEPTIDES FOR PRODUCTION OF 7-DEHYDROCHOLESTEROL AND METHODS OF USE THEREOFOctober 2024February 2025Allow401NoNo
18920640SYSTEM AND METHOD FOR CONTROLLED POLYMER DEPOLYMERIZATIONOctober 2024November 2025Abandon1311NoNo
18914016COMPOSITIONS FOR PREVENTING OR TREATING CORONAVIRUS INFECTIONSOctober 2024September 2025Allow1111NoNo
18909568METHODS OF PREPARING A POSTBIOTIC COMPOSITIONOctober 2024January 2026Allow1550YesNo
18901009BONE GELATIN PROCESSSeptember 2024June 2025Allow820NoNo
18894709Compositions and Methods for Making Epigenetic ModificationsSeptember 2024March 2025Allow510YesNo
18889088COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSSeptember 2024May 2025Allow820NoNo
18886925HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEINSeptember 2024January 2025Allow410YesNo
18847017SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDESSeptember 2024February 2025Allow500YesNo
18882318RECOMBINANT CELL WALL HYDROLASESSeptember 2024December 2024Allow301NoNo
18824681PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESSeptember 2024November 2024Allow200YesNo
18810577MICROMOLECULAR TYPE III COLLAGEN PEPTIDE CAPABLE OF PROMOTING SECRETION OF TYPE III AND IV COLLAGENS, AND PREPARATION METHOD THEREFORAugust 2024April 2025Allow711NoNo
18799019FOOD COMPOSITION FOR IMPROVING BEHAVIORAL AND MOTOR FUNCTION CONTAINING ALDEHYDE DEHYDROGENASE FOR REDUCING ALDEHYDES PRODUCED BY OXIDATION OF ALCOHOLAugust 2024August 2025Allow1221YesNo
18775468PHENYL ALCOHOLS FROM GAS FERMENTATIONJuly 2024December 2025Abandon1730NoNo
18755691Fusion protein and its preparation method for intermediate polypeptide of SemaglutideJune 2024November 2024Allow510YesNo
18723639NOVEL PROMOTER VARIANT FOR CONSTITUTIVE EXPRESSION AND USES THEREOFJune 2024April 2025Allow1001YesNo
18750621High Fidelity Restriction EndonucleasesJune 2024October 2025Allow1610YesNo
18721879ZAVARZINIA COMPRANSORIS CAPABLE OF DEGRADING ORGANOPHOSPHORUS FLAME RETARDANT AND USE THEREOFJune 2024June 2025Allow1200YesNo
18747818Peptides for Characterization of Botulinum NeurotoxinsJune 2024March 2025Allow910NoNo
18741089DESTABILISING DOMAINS FOR CONDITIONALLY STABILISING A PROTEINJune 2024September 2025Allow1510YesNo
18740177SYSTEM AND METHOD FOR PRESERVING ALGAEJune 2024September 2025Abandon1520YesNo
18737619MICROORGANISMS AND METHODS FOR THE PRODUCTION OF OXYGENATED COMPOUNDS FROM HEXOSESJune 2024November 2025Abandon1710NoNo
18734239METHOD FOR EXPANDING PROPAGATION OF METARHIZIUM RILEYI MR006 AND USE THEREOFJune 2024April 2025Allow1020NoNo
18731571IMMOBILIZED ENZYMES FOR BIOELECTROCATALYSISJune 2024July 2025Allow1311YesNo
18406031OLFACTORY RECEPTOR INVOLVED IN THE PERCEPTION OF MUSK FRAGRANCE AND THE USE THEREOFMay 2024July 2025Allow1910YesNo
18674014NANOBUBBLES FOR ANAEROBIC PROCESSESMay 2024October 2025Allow1621YesNo
18672557COMPOSITIONS AND METHODS COMPRISING VARIANT MICROBIAL PROTEASESMay 2024July 2025Allow1310YesNo
18666610Mannanase Variants and Polynucleotides Encoding SameMay 2024March 2026Allow2231YesNo
18662446Enzyme Variants With Improved Ester Synthase PropertiesMay 2024April 2025Allow1110YesNo
18709446ENGINEERED SPLIT DHFR-BASED METHODS AND SYSTEMS FOR SELECTING CELLS THAT HAVE STABLY ACQUIRED A HETEROLOGOUS POLYNUCLEOTIDEMay 2024February 2026Abandon2111NoNo
18655606ENGINEERED HUMAN EXTRACELLULAR DNASE ENZYMES FOR DRUG CANDIDATE SELECTIONMay 2024March 2026Abandon2201NoNo
18648034PROCESSES AND SYSTEMS TO PRODUCE RENEWABLE ENERGY AND FIBER FROM CELLULOSE-RICH WASTE MATERIALSApril 2024April 2025Allow1111NoNo
18648209PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESApril 2024August 2024Allow300YesNo
18641530ENZYMATIC PRODUCTION OF HEXOSESApril 2024November 2025Allow1910NoNo
18626782ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATIONApril 2024March 2025Allow1111YesNo
18625448ALDEHYDE DEHYDROGENASE PRODUCING BACTERIA AND METHODS OF USING SAMEApril 2024July 2024Allow300YesNo
18619099Akkermansia Muciniphila and Product and Application ThereofMarch 2024December 2025Allow2150YesNo
18614748Construction Method and Applications of Glycosyltransferase BS-YjiC MutantMarch 2024September 2024Allow502YesNo
18615341BOTULINUM NEUROTOXIN BIOHYBRIDMarch 2024June 2025Abandon1501NoNo
18614665BONE GELATIN PROCESSMarch 2024August 2024Allow410NoNo
18613291GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN, OPTIMIZED VECTORS, AND USES THEREOFMarch 2024December 2025Allow2001YesNo
18613508OMNI-103 CRISPR NUCLEASEMarch 2024August 2025Allow1710NoNo
18612615METHODS AND COMPOSITIONS FOR THE ENZYMATIC PRODUCTION OF PSEUDOURIDINE TRIPHOSPHATEMarch 2024January 2025Allow1011YesNo
18693613METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING C. GLUTAMICUM STRAINS EXPRESSING MODIFIED GLUCONATE REPRESSOR PROTEINS GNTR1 AND GNTR2March 2024December 2024Allow920YesNo
18604927METHODS AND COMPOSITIONS FOR GENOME EDITINGMarch 2024December 2025Abandon2111NoNo
18603491ENGINEERED ELECTRODE FOR ELECTROBIOCATALYSIS AND PROCESS TO CONSTRUCT THE SAMEMarch 2024July 2025Allow1710NoNo
18602534GENETICALLY MODIFIED PROBIOTICS FOR ORAL DELIVERY OF RENIN-ANGIOTENSIN RELATED THERAPEUTIC PROTEINS AND PEPTIDESMarch 2024February 2026Allow2300YesNo
18601266METHODS OF MAKING CHITOSANMarch 2024September 2025Allow1800YesNo
18600332ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE JMarch 2024April 2025Abandon1310NoNo
18598993METHODS FOR RAPID SEPARATION AND PURIFICATION OF DNA TOPOLOGICAL FORMSMarch 2024March 2025Allow1210NoNo
18598286SYSTEMS FOR DETERMINING ADAMTS13 ENZYME ACTIVITYMarch 2024June 2025Allow1501YesNo
18595600ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEMarch 2024May 2025Allow1401YesNo
18688056POLYPEPTIDES AND USES THEREOFFebruary 2024May 2025Allow1411NoNo
18589147METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINSFebruary 2024August 2025Allow1820NoNo
18586709Polypeptides having Peptidoglycan Degrading Activity and Polynucleotides Encoding SameFebruary 2024January 2025Allow1100YesNo
18586929ENZYMES WITH RUVC DOMAINSFebruary 2024December 2024Allow921NoNo
18585684METHOD AND DEVICE FOR APPLYING PHASE ROTATION OPTIMIZED FOR WIDE BAND IN WIRELESS LAN SYSTEMFebruary 2024September 2024Allow710NoNo
18584363PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEFebruary 2024March 2025Allow1310NoNo
18582803Chimeric endolysin polypeptideFebruary 2024July 2024Allow500YesNo
18444590Compositions and Methods for Making Epigenetic ModificationsFebruary 2024June 2024Allow400YesNo
18441456Cell-Free Protein SynthesisFebruary 2024January 2026Allow2320YesNo
18438285CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOFFebruary 2024April 2025Allow1410YesNo
18433739METHOD FOR THE INCORPORATION OF FORMALDEHYDE INTO BIOMASSFebruary 2024March 2026Allow2511YesNo
18432802VARIANT LOVD POLYPEPTIDES AND THEIR USESFebruary 2024March 2025Allow1411NoNo
18432505MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYFebruary 2024March 2025Allow1300YesNo
18431554ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)February 2024September 2025Abandon2001NoNo
18431662RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEFebruary 2024February 2025Allow1300YesNo
18431885METHODS OF POPULATING A GASTROINTESTINAL TRACTFebruary 2024September 2025Abandon1901NoNo
18428104Recombinant Escherichia Coli for Producing L-tyrosine and Application ThereofJanuary 2024May 2025Allow1621NoNo
18424952MODIFIED IMMUNE CELLS HAVING ENHANCED FUNCTION AND METHODS FOR SCREENING THE SAMEJanuary 2024January 2025Allow1100YesNo
18291954LARGE SCALE PURIFICATION OF ANTIBODIESJanuary 2024July 2025Allow1721NoNo
18421303HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOFJanuary 2024October 2025Abandon2101NoNo
18419368HARVEST OPERATIONS FOR RECOMBINANT PROTEINSJanuary 2024March 2025Abandon1301NoNo
18417919METHODS, DEVICES, AND KITS FOR PURIFYING AND LYSING BIOLOGICAL PARTICLESJanuary 2024April 2025Abandon1511NoNo
18416843ICAM-1 TARGETED FUSION ENZYMESJanuary 2024February 2025Allow1300YesNo
18416306POLYMERASE ENZYME FROM PHAGE T4January 2024April 2025Abandon1501NoNo
18410876PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024March 2024Allow200YesNo
18410949PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024April 2024Allow300YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1656.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
139
Examiner Affirmed
95
(68.3%)
Examiner Reversed
44
(31.7%)
Reversal Percentile
46.5%
Lower than average

What This Means

With a 31.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1098
Allowed After Appeal Filing
242
(22.0%)
Not Allowed After Appeal Filing
856
(78.0%)
Filing Benefit Percentile
9.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1656 - Prosecution Statistics Summary

Executive Summary

Art Unit 1656 is part of Group 1650 in Technology Center 1600. This art unit has examined 13,705 patent applications in our dataset, with an overall allowance rate of 63.0%. Applications typically reach final disposition in approximately 31 months.

Comparative Analysis

Art Unit 1656's allowance rate of 63.0% places it in the 18% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1656 receive an average of 1.73 office actions before reaching final disposition (in the 36% percentile). The median prosecution time is 31 months (in the 46% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.